{"id":913657,"date":"2025-11-25T09:29:22","date_gmt":"2025-11-25T14:29:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/"},"modified":"2025-11-25T09:29:22","modified_gmt":"2025-11-25T14:29:22","slug":"akari-therapeutics-announces-release-of-the-next-ceo-corner-segment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/","title":{"rendered":"Akari Therapeutics Announces Release of the Next CEO Corner Segment"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Access the Akari CEO Corner\u00a0<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w0mqI-Zgxo0hvRE1YeqfJmQWnahN7_nxWkpJPP6Mz_bxFb6lXwxZCViIXQOc_pb6o5XAAvbbHON4ngseDVnHUg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em>here<\/em><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">BOSTON and LONDON, Nov.  25, 2025  (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=75z2WonlTDffqdmfLS2aigeHJkKuELH_nUmdly0lifjWanExbEi65fcfOMjAbmK2pq1k7ljoTBPYyfqHHoICFUoMnCeftw01KO2bPAHe3to=\" rel=\"nofollow\" target=\"_blank\">Company\u2019s website<\/a>. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company\u2019s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the growing capabilities of Akari\u2019s next-generation ADC discovery platform and the Company\u2019s mission to advance differentiated therapies for patients.<\/p>\n<p align=\"justify\">The CEO Corner segment is now available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w0mqI-Zgxo0hvRE1YeqfJlCWnvJfhNz76ONwuqZoWfN-4074BLHGhlu7IUMWNHUCSuhSEaX3B3QudCgcL1pkvg==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Akari Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.<\/p>\n<p align=\"justify\">For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Av0oIUbpPhqlt4fUUliMlL3sLX54BAAJeKvXCyoLIw4oXr3O20Vh8VjoEiKyOfntE0fhoO-Tt5L6IFlDY0jvfo3i-O_d5CC-iamG0t8SEQ0=\" rel=\"nofollow\" target=\"_blank\">www.akaritx.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DJlCZNcEnbr1W0PLD2XIZy1BFzZ13G3bo1HaDExmjk9bxQFopRV_bBN3dAlW9d6iMl4XDC0gWxrThybWKxZEfA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_8nZKkwnqj2I4AtSHrhqwtXUw0jD8sa62SvICegBaxbp3Ig5WTI6X-aHzodoO4_KkbiDJL9L04U9zUZDL1NUFJ7xFBEkJHXhIjXUg_1wGcw=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact <\/strong>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC <br \/>Jenene Thomas <br \/>908-824-0775 <br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Fru1l1II_MgNWpu1dSoRrpbHkDgEmty1jGX8Qh272OFlCj9IZYPb-VO1ecptTydKMk-p6zbk_6kkeRnk3fuJA==\" rel=\"nofollow\" target=\"_blank\">AKTX@jtcir.com<\/a><\/u>\u00a0 \u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWM0NDU0NWEtZDQyNi00OGFiLTk1ZjUtNzNmMTllM2FjYjgzLTEwMzE4MzUtMjAyNS0xMS0yNS1lbg==\/tiny\/Akari-Therapeutics-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Access the Akari CEO Corner\u00a0 here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company\u2019s website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company\u2019s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the growing capabilities of Akari\u2019s next-generation ADC discovery platform and the Company\u2019s mission to advance differentiated therapies for patients. The CEO Corner segment is now available here. About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akari Therapeutics Announces Release of the Next CEO Corner Segment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913657","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Access the Akari CEO Corner\u00a0 here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company\u2019s website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company\u2019s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the growing capabilities of Akari\u2019s next-generation ADC discovery platform and the Company\u2019s mission to advance differentiated therapies for patients. The CEO Corner segment is now available here. About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome &hellip; Continue reading &quot;Akari Therapeutics Announces Release of the Next CEO Corner Segment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T14:29:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akari Therapeutics Announces Release of the Next CEO Corner Segment\",\"datePublished\":\"2025-11-25T14:29:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/\",\"name\":\"Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\",\"datePublished\":\"2025-11-25T14:29:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akari Therapeutics Announces Release of the Next CEO Corner Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/","og_locale":"en_US","og_type":"article","og_title":"Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk","og_description":"Access the Akari CEO Corner\u00a0 here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company\u2019s website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company\u2019s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the growing capabilities of Akari\u2019s next-generation ADC discovery platform and the Company\u2019s mission to advance differentiated therapies for patients. The CEO Corner segment is now available here. About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome &hellip; Continue reading \"Akari Therapeutics Announces Release of the Next CEO Corner Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T14:29:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akari Therapeutics Announces Release of the Next CEO Corner Segment","datePublished":"2025-11-25T14:29:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/","name":"Akari Therapeutics Announces Release of the Next CEO Corner Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=","datePublished":"2025-11-25T14:29:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MTUyMiM3MjkwMjIyIzIwMjAyNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-release-of-the-next-ceo-corner-segment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akari Therapeutics Announces Release of the Next CEO Corner Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913657"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}